CEOInterviews.AI
Start App
Get an email when Mark Cuban gives a new interview
One email per new interview. Unsubscribe in one click.
Mark Cuban
Co-founder; minority owner, Dallas Mavericks, Cost Plus Drugs

Why Healthcare Prices Are Like Fight Club w/ Mark Cuban, Co-Founder, Cost Plus Drugs

📅 Jun 26, 2026 CareTalk: Healthcare. Unfiltered. Podcast 36 MIN 56653 VIEWS 74 SEGMENTS · 2 SPEAKERS
Nobody at the pharmacy counter knows the real price of their medication, and almost nobody in the system actually wants them to. Mark Cuban, Co-Founder of Cost Plus Drugs, joins host John Driscoll on CareTalk to discuss why pharmacy benefit managers control 85% of drug formularies in this country, how spread pricing quietly inflates the cost of everything from generics to hip replacements, and why true price transparency, not just lower prices, is the real disruption Cost Plus Drugs has brought to a $5 trillion industry. 🎙️⚕️ABOUT MARK CUBAN Mark Cuban is a self-made billionaire entrepreneur...

Questions asked in this interview

12
  1. 0:59Tell us, maybe start a little bit like after basketball and TV and digital, what got you intrigued by healthcare?
  2. 3:22And the vast majority of Americans assume that they're getting a fair price at the pharmacy. What are they missing?
  3. 10:24Allegedly, you know, the insured people are paying for that rebate, right?
  4. 13:53So, Mark, how does Cost Plus Drugs compare to GoodRx or the cash cards?
  5. 16:31Is anyone, just to be really clear, is anyone offering true transparent Cost Plus Drugs to compete with you?
  6. 16:59And at least today, are you still pretty much completely generics oriented or are you starting to build brands?
  7. 18:46What would you like to see in terms of PBM reform from DC?
  8. 20:38First of all, that question, why would an American company need a company in Ireland?
  9. 22:04Do I believe you had ended up with a relationship with Blue Shield?
  10. 27:53Can you talk a little bit about that?
  11. 29:07Have you cracked that insurance company wall yet?
  12. 29:42So, is that a reform idea that we should encourage folks to push at a state level?
John Driscoll 0:00 ↗
Mark Cuban is an American original. He became a billionaire in 1999 when he disrupted the broadcast industry and sold broadcast.com to Yahoo. He achieved every kid's dream in 2000. If he couldn't play for a professional sports team, he bought one. When he bought the Dallas Mavericks and helped lead them to a championship in 2011, he became a famous face as an entrepreneur, as an investor on TV's Shark Tank, and honestly a hero to my kids and a lot of other budding entrepreneurs. But today we're going to talk about how he's disrupting and taking on the $6 trillion healthcare market and particularly the excess margins.
Welcome to CareTalk, America's home for incisive debate on healthcare business and politics. I'm John Driscoll, the chairman of the UConn Health System, and Mark, welcome.
Mark Cuban 0:56 ↗
Thanks for having me, John. I'm excited to be here.
John Driscoll 0:59 ↗
Tell us, maybe start a little bit like after basketball and TV and digital, what got you intrigued by healthcare?
Mark Cuban 1:10 ↗
You know, as an entrepreneur and somebody who likes to do disruptive things, I always look at industries that people don't like, where the biggest incumbents aren't their favorites to do business with, and they wish they had an alternative, and start from there. And then I got a cold email from my co-founder, Dr. Alex Oshmyansky, and he wanted to do a compounding manufacturing center for drugs that go on the FDA short supply list, things like pediatric cancers. And you can't say no to helping little kids get their pediatric cancer medications, and that led me to learn a lot more about how opaque the pharmaceutical side of the industry is, and that led to Cost Plus Drugs launching in January of '22.
John Driscoll 1:53 ↗
I just remember that early discovery phase when you were talking to, I think I talked to you once or twice, you talked to a lot of my friends, and the patience and the care with which you got into the details of how our crazy healthcare system works. But you could have gone after anything. What intrigued you about going after drugs and drug margins and, you know, what's turned, what right now is probably one out of every five healthcare dollars that insurers cover is now drugs.
Mark Cuban 2:21 ↗
It was a path of least resistance, to be candid. You know, nobody knew what the price of a medication was. The stories of hearing people at the pharmacy counters turning around and not being able to get their drugs are tragic. And so, when I looked, it was very self-evident that nobody knew not only the price but the cost of a medication, and nobody trusted the economic side of pharmacy or medical. And so, it just made natural sense to me as an entrepreneur that if I showed my cost for a medication and I showed my markup and had it at 15%, not only would we be less expensive, but we would be trusted. And that's the key that was missing. People don't trust the economic side of their healthcare. They trust their doctor, but they don't trust the bill that they're going to get or what it's going to cost. And by, you know, having that ultimate transparency of cost and markup, that was unique and that would allow us to not only be less expensive, but to be trusted. And that's what got us there.
John Driscoll 3:22 ↗
And the vast majority of Americans assume that they're getting a fair price at the pharmacy. What are they missing?
Mark Cuban 3:31 ↗
They're missing, you know, they trust their pharmacist and assume that the pharmacist is going to do the right thing for them. What they're missing is there are these enormous conglomerates that dominate the economics of not just pharmacy but all of healthcare. And in pharmacy specifically, they're called pharmacy benefit managers, and they effectively control, you know, 85% of the formularies, which determines what drugs are available to healthcare members and at what price. And with that control, they've been able to dominate the pharmacy market and really define pricing.
John Driscoll 4:09 ↗
Well, and I think the other thing is that it's all done in the shadows. You know, one of the amazing things that you've been able to do is really talk about true pricing. I think the MD Anderson study recently said that it can often cost a $50 copay for a generic prescription that people can get for $5 on the Cost Plus Pharmacy. I mean, it was just mind-blowing.
Mark Cuban 4:35 ↗
Yeah, it's crazy. I mean, whether it's what Medicare spends on drugs, whether it's insurance companies. I was just talking to an insurance company and they literally don't know what their actual net price is because of all the rebates and fees. And where the industry is really turned upside down when it comes to patients starts with distribution. And if this is too much inside baseball, just tell me.
John Driscoll 4:59 ↗
No, no, roll on. You're talking to the right people.
Mark Cuban 5:03 ↗
So, when for distribution of drugs to pharmacies, that's dominated by three companies. And those three companies control more than 90% of the pharmaceutical transactions. And effectively, they buy from the manufacturers, inventory them, and then ship them to the pharmacies. Simple, right? A typical Shark Tank episode, except these companies, they're so dominant, they do hundreds of billions of dollars in revenue each. And you would think companies with that level of market dominance could go to the BMSs, the Pfizers, the Lillys, etc., and say, 'Hey, we want the best price we can possibly get.' And if that's what you thought, you would be wrong. Because believe it or not, when those huge distribution companies buy from those brands, they literally pay the list price. And then, if they pay within 30 days, I think it is, they get a 1.5% discount. And then, if they provide some data, they get another 3.5%, so typically it's a 5% discount. So, for a drug that's retail price is $600, the biggest distributors in the world are paying $570.
That creates the problem. Because when they pay $570 for a $600 list price drug, or, you know, $950 for a $1,000 list price drug, that's the least amount that they can charge to a pharmacy. And if that's the least a pharmacy can pay, $570 in this example, someone comes in that's uninsured, they can't sell it for less than $570. Somebody comes in and they're in a deductible phase, they can't sell it for less than $570. So, that right there is what creates all the disconnect in the pricing for pharmacy. Now, the question becomes, why are the brand manufacturers, you know, the Pfizers, the BMSs, etc., willing to do this? Because they actually, in some cases publish, but they have a net price that they actually receive. And even though they sold that drug for $570, 5% discount, they receive $570 initially, but then they're paying out rebates and fees to the pharmacy benefit managers, which makes their net price about $300.
Now, I went to them and I said, 'Well, if your net price is $300, why don't you just sell it for $310 to the distributor? You would make more money.' And then the distributor could sell it for $340 to the pharmacy, and the distributor would make more money than they were, and now the pharmacy, having paid $340 instead of $570, can sell for $345 or $350 to the uninsured patient, which still may be too expensive, but at least gives them a chance. Same with those in their deductible phase. And so for the manufacturer, they would make more money, reach more patients, the patients would have better adherence, and everybody would be ahead. And I asked them, why do you not do this? And multiple CEOs have said, because those big PBMs that control the formularies for 85% of insured people in this country, well guess what? They told us if we do that, they will diminish our positioning on their formularies. So anybody who checks their own pharmacy benefit plan will see, you know, tier one is a $5 copay for generics and then it goes up from there. If for a brand drug the copay goes from $25 to $75 or $100 or turns into co-insurance, the sales to that manufacturer, particularly if it's across their entire portfolio, is going to drop dramatically. And so that's the threat that the PBMs use.
And it's also the reason why costplusdrugs.com has pretty much every generic but only a smattering of brand drugs, because those same PBMs have told those same CEOs of the brand manufacturers, if you deal with costplusdrugs, we will do the same thing and diminish your positioning on the formulary. Why would they do it for just a little upstart company like ours? Because they know that if we show the net price and only mark it up 15%, that $300 drug selling for $345 is going to really disrupt their pricing with all these commercial entities, all these companies that are offering these plans to their members, to their employees and their families. And so they basically have done all they could to lock us out, but it's because of these PBMs and the insurance companies that they own or are owned by them that completely have destroyed the economics for patients across this country.
John Driscoll 10:04 ↗
Well, and I think the other thing that, and I think you probably know this, but a lot of the insurance companies have their hand in the pocket of the PBM margin. So it's a co-dependent relationship.
Mark Cuban 10:18 ↗
It's a, they're vertically integrated. Yeah, they're vertically integrated.
John Driscoll 10:24 ↗
And even when they're not, they all fought the rebates at point of sale where the rebate would flow down. Allegedly, you know, the insured people are paying for that rebate, right? Because they're paying the insurance, the employer or the employee.
Mark Cuban 10:38 ↗
Well, your sickest employees, your sickest people pay the rebates because if no one was sick, there'd be no rebates.
John Driscoll 10:46 ↗
And that is going into margin, which then they say is keeping their rates down when rates are going up. I mean, it's sort of, it's a...
Mark Cuban 10:55 ↗
It's obfuscation, right? There's no transparency from their side. You know, healthcare contracts are like Fight Club. The number one rule of Fight Club is that you don't talk about Fight Club. The number one rule of any healthcare contract is by law, they have confidentiality agreements. You're not allowed to disclose anything.
John Driscoll 11:15 ↗
Unemployable if you tell, if you break Fight Club rules.
Mark Cuban 11:22 ↗
Exactly right. 100%. And so people don't know the information asymmetry with states, with big companies, they have nothing. And we're talking about pharmacy. It's even worse on the medical side. You know, the spread that happens when somebody goes in for a hip replacement and your employer is contracted with a big insurance company, you know, the contract, you might have access to the information that says that hip replacement is supposed to be $25,000. But that insurance company ain't paying the provider the full $25,000. Right? They're paying them whatever, making the spread, and you have no idea what it is because it's a trade secret to know what that insurance company that you hired, by the way, that you hired to work for you, that's supposed to be acting in your fiduciary interest. They won't tell you.
John Driscoll 12:18 ↗
So, how does, I want to get back to the industry piece, but okay, a consumer is upset. My mother's 92 years old. There's a bunch of drugs involved. Like, how does she get access to the Cost Plus Drugs if she's locked out of the insurance, if she can't get out of it through her Blue Cross Blue Shield plan in Massachusetts?
Mark Cuban 12:37 ↗
So, we have a lot of people who are on Medicare Advantage and traditional Medicare plans because very often our pricing is less than their co-insurance. And so, what happens to make it work, you just go to costplusdrugs.com and in the upper right-hand side, you can add your account, you put in your credit card, it'll tell you where to tell your doctor to send the script because they can do it right from their EMR, right? And they just send it right to Mark Cuban Cost Plus Drugs and it's easy. And then when the script is there, we'll send you an alert, 'Hey, we received your prescription for whatever it may be, right?' And then you go in there and it's just like any other e-commerce event. Now, I know it's tough for a 92-year-old sometimes, so you may have to help her.
John Driscoll 13:23 ↗
I mean, she's got three sons. We can send...
Mark Cuban 13:25 ↗
Right. So, you got people to help her. And actually, we just upgraded the system so that if there is a dependent who is managing it for somebody who's not capable of using it, that it'll work now. And so, you just put it in there, they'll ship it to her, and you can do a 30, 60, 90, 365-day supply just depending on what the circumstances are and, you know, how much you want to save. And that's it.
John Driscoll 13:48 ↗
Live forever. We're going to go with the longer version.
Mark Cuban 13:50 ↗
That's the whole idea, right? That's the whole idea.
John Driscoll 13:53 ↗
So, Mark, how does Cost Plus Drugs compare to GoodRx or the cash cards? There's a lot of, in the generics world and the cash world, which you're playing in, there's a lot of confusing things for consumers. Like, how does a consumer think about...
Mark Cuban 14:11 ↗
Here's the difference. When you go to costplusdrugs.com, you see our price, and that price is available to everybody. It doesn't matter who you are, doesn't matter your circumstances, doesn't matter what city or state you're in, you get the same price. GoodRx and some of the other discount cards, they do deals with pharmacies and they say, 'You know what? If you offer a better price for this week, you're going to get what we estimate to be X number of prescriptions, and you'll be able to retain those people. They'll keep on coming back. So, let's run a discount,' which may or may not be as cheap as Cost Plus Drugs, typically not, but when people go look at using one of the discount cards, it'll appear to be a much better price because the CVS is lower than the Walgreens in one city, and the Walgreens is lower than the CVS in another city, and next week the price can be completely different. And then on top of that...
John Driscoll 15:05 ↗
That is a really important point for consumers. It literally can change by location and by geography and by time. And the confusion's kind of part of the point.
Mark Cuban 15:18 ↗
Right. Oh, for sure. Right. And on top of that, they literally charge the pharmacy for sending them traffic. It's kind of like you make it up in toilet paper and Cokes, you know? And so, particularly the independent pharmacies hate it. So, in response to that, we created what's called teamcubancard.com. teamcubancard.com, right? Where if somebody doesn't want to wait for mail order from costplusdrugs.com, you can go to Team Cuban Card and we have 17,000 pharmacies that we work with. Now, I'm going to be honest with you, if it's a five or seven-dollar drug, because we pay the pharmacy a $12 fill fee for their time and support, right? We may be a little bit more expensive than mail order or GoodRx, which charges the pharmacy, but for anything over $15, we're going to be competitive and you can pick it up locally there. So, you just go to Team Cuban Card, you look up the medication, you print out the same type of card or you just have it on your phone, you walk in, you tell the doctor to send it to the Walgreens or to the Albertsons or whatever it is, and you walk in with your screen or you print it out, and you get the Cost Plus type price.
John Driscoll 16:31 ↗
Is anyone, just to be really clear, is anyone offering true transparent Cost Plus Drugs to compete with you?
Mark Cuban 16:40 ↗
No. We're still four years in, four and a half years in. The only company that publishes a price list, the only company that has the exact same price for everybody without any membership, without any upfront fees, without any after effects. Yeah, none of that stuff at all. The price you see is what you get plus shipping.
John Driscoll 16:59 ↗
And I think, you know, we talk about a public benefit corporation. When one out of three Americans don't fill their script often because they can't afford it, what you're doing is a true public service. And at least today, are you still pretty much completely generics oriented or are you starting to build brands?
Mark Cuban 17:19 ↗
Go back to what I said before, right? Because we're starting to build brands, but the brand manufacturers are still telling us that the PBMs don't want them to work with us. And that's an inhibitor for us. That's a challenge. But one by one we're adding more, like we just added... Yeah, we were able to work something out there. We're awesome. And so BMS, we put that together and it's $345.

35 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Cuban, M. (2026, June 26). Why Healthcare Prices Are Like Fight Club w/ Mark Cuban, Co-Founder, Cost Plus Drugs [Interview transcript]. CareTalk: Healthcare. Unfiltered. Podcast. CEOInterviews.AI. https://ceointerviews.ai/interview/3082387/

MLA

Mark Cuban. "Why Healthcare Prices Are Like Fight Club w/ Mark Cuban, Co-Founder, Cost Plus Drugs." CareTalk: Healthcare. Unfiltered. Podcast, 26 Jun. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3082387/.

BibTeX
@misc{cuban2026_3082387,
  author       = {Mark Cuban},
  title        = {Why Healthcare Prices Are Like Fight Club w/ Mark Cuban, Co-Founder, Cost Plus Drugs},
  howpublished = {Interview transcript, CareTalk: Healthcare. Unfiltered. Podcast. CEOInterviews.AI},
  year         = {2026},
  month        = {jun},
  url          = {https://ceointerviews.ai/interview/3082387/},
  note         = {Speaker-attributed transcript with timestamps}
}